Home Metabolism IDO/TDO

IDO/TDO

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S8037 Necrostatin-1 (Nec-1) Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Cell Res, 2025, 10.1038/s41422-025-01167-8
Signal Transduct Target Ther, 2025, 10(1):341
Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1317
Verified customer review of Necrostatin-1 (Nec-1)
S7910 Epacadostat (INCB024360) Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with an IC50 of 10 nM, and it displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).
Immunity, 2025, 58(1):247-262.e9
Mol Cell Proteomics, 2025, 24(9):101048
Commun Chem, 2025, 8(1):277
Verified customer review of Epacadostat (INCB024360)
S7111 IDO-IN-2 IDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
Acta Pharm Sin B, 2022, 12(6):2695-2709
Small, 2022, e2205694
Int J Mol Sci, 2022, 23(7)3981
Verified customer review of IDO-IN-2
S7756 Indoximod Indoximod, a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2.This product has poor solubility, animal experiments are available, cell experiments please choose carefully!
Front Immunol, 2024, 15:1331480
iScience, 2024, 27(10):110862
Nat Commun, 2023, 14(1):5753
S8957 Navoximod Navoximod (GDC-0919, NLG-919) is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) pathway with Ki of 7 nM and EC50 of 75 nM.
J Colloid Interface Sci, 2025, 686:1019-1032
Commun Chem, 2025, 8(1):277
Acta Pharm Sin B, 2022, 12(6):2695-2709
S8629 Linrodostat (BMS-986205) Linrodostat (BMS-986205, ONO-7701) is an irreversible inhibitor of IDO1 with an IC50 of 1.7 nM. It inhibits kynurenine production with IC50 values of 1.7, 1.1 and > 2000 in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays.
Front Chem, 2022, 10:998013
Front Oncol, 2021, 11:679517
Eur Respir J, 2020, 2000443
S8657 PF-06840003 PF-06840003 (EOS200271) is a highly selective orally bioavailable IDO-1 inhibitor. Although this compound has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size.
Front Immunol, 2023, 14:1100041
J Immunother Cancer, 2022, 10(3)e004414
Cell, 2020, 182(5):1252-1270.e34
S8368 LM10 LM10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50 values of 0.62 and 2 μM for human and mouse TDO, respectively.
Sci Adv, 2023, 9(5):eadd6995
Mol Med Rep, 2021, 23(6)445
Eur J Med Chem, 2018, 160:133-145
S8557 IDO inhibitor 1 IDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM.
J Immunol, 2023, 211(2):261-273
Eur Respir J, 2020, 2000443
S7587 Epacadostat (INCB024360) analogue Epacadostat (INCB024360) analogue (INCB14943) is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM.
Biomed Pharmacother, 2024, 179:117412
Front Immunol, 2022, 13:966514
Oncoimmunology, 2017,